MKK7

By Targets:	Apoptosis (1) Autophagy (1) Calcium Channel (1) CCR (1) CXCR (1) DNA/RNA Synthesis (2) JAK (1) JNK (5) MDM-2/p53 (1) NF-κB (1) p38 MAPK (5) PKC (3) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (10) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122872

MKK7-COV-9	p38 MAPK	Cancer
MKK7-COV-9 is a potent and selective covalent inhibitor of *MKK7* and targets a specific protein-protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC₅₀ of 4.98 μM .

HY-152185

BSJ-04-122 1 Publications Verification	p38 MAPK	Cancer
BSJ-04-122 is a covalent *MKK4/7* dual inhibitor. BSJ-04-122 inhibits MKK4 and MKK7 with IC₅₀ values of 4 nM and 181 nM, respectively. BSJ-04-122 can be used for the research of cancer .

HY-100538

DTP3 1 Publications Verification	DNA/RNA Synthesis JAK	Cancer
DTP3 TFA is a potent and selective *GADD45β/MKK7* inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway .

HY-152860

Darizmetinib HRX-0215	p38 MAPK JNK NF-κB MDM-2/p53	Cancer
Darizmetinib (HRX-0215) is an orally active, potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4). Darizmetinib leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Darizmetinib is promising for research of preventing liver failure after extensive oncological liver resections or transplantation of small liver grafts .

HY-100538A

DTP3 TFA 1 Publications Verification	DNA/RNA Synthesis JNK	Cancer
DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway .

HY-13866

Ro 31-8220 mesylate Maximum Cited Publications 13 Publications Verification Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate	PKC	Cardiovascular Disease Neurological Disease Cancer
Ro 31-8220 mesylate is a potent PKC inhibitor, with IC₅₀s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC₅₀s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.

HY-176228

WEIZ-WX-04-008	p38 MAPK	Others
WEIZ-WX-04-008 (Compound 1) is a covalent Lysine-targeting *MKK7* inhibitor with IC₅₀ of 738 nM .

HY-14411

JNK-1-IN-1	JNK	Cancer
JNK-1-IN-1 is a JNK-1 inhibitor. JNK-1-IN-1 also inhibits *MKK7* with an IC₅₀ of 7.8μM. JNK-1-IN-1 bind to MKK7cp and acts as an inhibitor of JNK-1 .

HY-N11723

Catenarin Katenarin	CCR CXCR p38 MAPK JNK Calcium Channel	Infection Metabolic Disease Inflammation/Immunology
Catenarin, an anthraquinone compound, inhibits CCR5- and CXCR4-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and *MKK7*), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice ^[1][2].

HY-13866A

Ro 31-8220 Bisindolylmaleimide IX	PKC	Cardiovascular Disease Neurological Disease
Ro 31-8220 is a potent PKC inhibitor, with IC₅₀s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC₅₀s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.

HY-13866R

Ro 31-8220 mesylate (Standard)	PKC	Cardiovascular Disease Neurological Disease Cancer
Ro 31-8220 (mesylate) (Standard) is the analytical standard of Ro 31-8220 (mesylate). This product is intended for research and analytical applications. Ro 31-8220 mesylate is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.

HY-RS26286

Map2k7 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Map2k7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Map2k7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Map2k7 Rat Pre-designed siRNA Set A Map2k7 Rat Pre-designed siRNA Set A

HY-RS08045

MAP2K7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MAP2K7 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP2K7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAP2K7 Human Pre-designed siRNA Set A MAP2K7 Human Pre-designed siRNA Set A

HY-N7394A

(-)-Zuonin A 1 Publications Verification D-Epigalbacin	JNK	Cancer
(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC₅₀s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively .

HY-N4006

Isoangustone A	Apoptosis Autophagy	Inflammation/Immunology Cancer
Isoangustone A is an anticancer and anti-inflammatory agent. Isoangustone A induces cancer cells apoptosis and autophagic cell death .

HY-RS19790

Map2k7 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Map2k7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map2k7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Map2k7 Mouse Pre-designed siRNA Set A Map2k7 Mouse Pre-designed siRNA Set A

Cat. No.	Product Name	Target	Research Area

HY-100538

DTP3 1 Publications Verification	DNA/RNA Synthesis JAK	Cancer
DTP3 TFA is a potent and selective *GADD45β/MKK7* inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway .

HY-100538A

DTP3 TFA 1 Publications Verification	DNA/RNA Synthesis JNK	Cancer
DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7394A

(-)-Zuonin A 1 Publications Verification D-Epigalbacin	Structural Classification Classification of Application Fields Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields Cancer	JNK
(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC₅₀s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively .

HY-N4006

Isoangustone A	Structural Classification Flavonoids Flavones Leguminosae Source classification Plants Glycyrrhiza uralensis Fisch.	Apoptosis Autophagy
Isoangustone A is an anticancer and anti-inflammatory agent. Isoangustone A induces cancer cells apoptosis and autophagic cell death .

HY-N11723

Catenarin Katenarin	Quinones Structural Classification Microorganisms Anthraquinones Source classification	CCR CXCR p38 MAPK JNK Calcium Channel
Catenarin, an anthraquinone compound, inhibits CCR5- and CXCR4-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and *MKK7*), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice ^[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82902

	MEK7 Antibody (YA2647) MAP2K7; JNKK2; MEK7; MKK7; PRKMK7; SKK4; Dual specificity mitogen-activated protein kinase kinase 7; MAP kinase kinase 7; MAPKK 7; JNK-activating kinase 2; MAPK/ERK kinase 7; MEK 7; Stress-activated protein kinase kinase 4; SAPK kinase 4; S	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	MEK7 Antibody (YA2647) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2647), targeting MEK7, with a predicted molecular weight of 47 kDa (observed band size: 47 kDa). MEK7 Antibody (YA2647) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS26286

Map2k7 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Map2k7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Map2k7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS08045

MAP2K7 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MAP2K7 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP2K7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS19790

Map2k7 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Map2k7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map2k7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Oligonucleotides